top of page

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—12/ 14/20-01/18/21

JAMA. Published online February 12, 2021. doi:10.1001/jama.2021.1967

In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for 2 mRNA-based vaccines for prevention of coronavirus disease 2019 (COVID-19): Pfizer-BioNTech COVID-19 vaccine (EUA issued December 11; 2 doses, 3 weeks apart) and Moderna COVID-19 vaccine (EUA issued December 18; 2 doses, 1 month apart). Shortly after each authorization, the Advisory Committee on Immunization Practices issued interim recommendations for use.1,2

Read more here :

1 view0 comments

Recent Posts

See All
bottom of page